PureTech Health Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BY2Z0H74
GBP
1.16
-0.24 (-17.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

372.48 k

Shareholding (Dec 2024)

FII

0.00%

Held by 0 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 1.71%

  • The company has been able to generate a Return on Equity (avg) of 1.71% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Operating profit has grown by an annual rate 0.56% of over the last 5 years

 
3

The company declared positive results in Dec'24 after negative results in Jun'24

4

With ROE of 11.47%, it has a very attractive valuation with a 1.10 Price to Book Value

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 304 Million (Small Cap)

stock-summary
P/E

10.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.83

stock-summary
Return on Equity

11.47%

stock-summary
Price to Book

1.11

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.76%
0%
-11.76%
6 Months
-31.52%
0%
-31.52%
1 Year
-48.39%
0%
-48.39%
2 Years
-51.73%
0%
-51.73%
3 Years
-31.6%
0%
-31.6%
4 Years
-69.58%
0%
-69.58%
5 Years
-56.05%
0%
-56.05%

PureTech Health Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-12.70%
EBIT Growth (5y)
0.56%
EBIT to Interest (avg)
-17.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.02
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
0
ROE (avg)
1.71%

Valuation key factors

Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.10
EV to EBIT
-0.80
EV to EBITDA
-0.82
EV to Capital Employed
1.59
EV to Sales
14.65
PEG Ratio
0.08
Dividend Yield
NA
ROCE (Latest)
-199.17%
ROE (Latest)
11.47%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by PureTech Health Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.74% vs -78.74% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 140.49% vs -78.07% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.80",
          "val2": "2.70",
          "chgp": "40.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.70",
          "val2": "-113.60",
          "chgp": "8.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.90",
          "val2": "10.90",
          "chgp": "-27.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.00",
          "val2": "64.80",
          "chgp": "-112.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "21.70",
          "val2": "-53.60",
          "chgp": "140.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-28,188.70%",
          "val2": "-43,903.90%",
          "chgp": "1,571.52%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
3.80
2.70
40.74%
Operating Profit (PBDIT) excl Other Income
-103.70
-113.60
8.71%
Interest
7.90
10.90
-27.52%
Exceptional Items
-8.00
64.80
-112.35%
Consolidate Net Profit
21.70
-53.60
140.49%
Operating Profit Margin (Excl OI)
-28,188.70%
-43,903.90%
1,571.52%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 40.74% vs -78.74% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 140.49% vs -78.07% in Dec 2023

stock-summaryCompany CV
About PureTech Health Plc stock-summary
stock-summary
PureTech Health Plc
Pharmaceuticals & Biotechnology
PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.
Company Coordinates stock-summary
Company Details
501 Boylston St Ste 6102 , BOSTON MA : 02116-3769
stock-summary
Tel: 1 617 4822333
stock-summary
Registrar Details